A. Clayborn

A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer

Jason B. White, J. Stec, W. Symmans, 2020, Investigational New Drugs.

Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer.

Jeffrey T. Chang, Jason B. White, G. Hortobagyi, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy

Jeffrey T. Chang, G. Hortobagyi, W. Symmans, 2023, Investigational New Drugs.

A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer

W. Symmans, V. Valero, N. Ibrahim, 2023, Breast Cancer Research and Treatment.

Deep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast Cancer

B. Adrada, Jingfei Ma, R. Candelaria, 2023, Cancers.